You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 12, 2025

Fluticasone propionate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for fluticasone propionate and what is the scope of freedom to operate?

Fluticasone propionate is the generic ingredient in twenty branded drugs marketed by Glaxosmithkline, Glaxo Grp Ltd, Fougera Pharms, Cosette, Encube, Nesher Pharms, Padagis Israel, Glenmark Pharms Ltd, Bright, Chartwell Rx, Taro Pharm Inds, Teva Pharm, Haleon Us Holdings, Apotex, Aurobindo Pharma Ltd, Hikma, Rubicon Research, Optinose Us Inc, Teva Pharms Usa, and Mylan, and is included in thirty-eight NDAs. There are forty-five patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Fluticasone propionate has eight hundred and fourteen patent family members in forty countries.

There are twenty-four drug master file entries for fluticasone propionate. Seventy-one suppliers are listed for this compound.

Drug Prices for fluticasone propionate

See drug prices for fluticasone propionate

Drug Sales Revenue Trends for fluticasone propionate

See drug sales revenues for fluticasone propionate

Recent Clinical Trials for fluticasone propionate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Eurofarma Laboratorios S.A.Phase 3
Humanis Saglık Anonim SirketiPhase 1
SanofiPhase 3

See all fluticasone propionate clinical trials

Pharmacology for fluticasone propionate
Paragraph IV (Patent) Challenges for FLUTICASONE PROPIONATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
FLOVENT HFA Inhalation Aerosol fluticasone propionate 0.22 mg/inh 021433 1 2021-10-29
FLOVENT HFA Inhalation Aerosol fluticasone propionate 0.11 mg/inh 021433 1 2016-12-23
CUTIVATE Lotion fluticasone propionate 0.05% 021152 1 2008-07-28

US Patents and Regulatory Information for fluticasone propionate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharm AIRDUO DIGIHALER fluticasone propionate; salmeterol xinafoate POWDER;INHALATION 208799-004 Jul 12, 2019 DISCN Yes No 11,344,685*PED ⤷  Try for Free Y ⤷  Try for Free
Teva Pharm ARMONAIR DIGIHALER fluticasone propionate POWDER;INHALATION 208798-005 Feb 20, 2020 DISCN Yes No 10,124,131*PED ⤷  Try for Free Y ⤷  Try for Free
Teva Pharm AIRDUO DIGIHALER fluticasone propionate; salmeterol xinafoate POWDER;INHALATION 208799-004 Jul 12, 2019 DISCN Yes No 11,173,259*PED ⤷  Try for Free Y ⤷  Try for Free
Teva Pharm ARMONAIR DIGIHALER fluticasone propionate POWDER;INHALATION 208798-004 Feb 20, 2020 DISCN Yes No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for fluticasone propionate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva Pharm ARMONAIR DIGIHALER fluticasone propionate POWDER;INHALATION 208798-005 Feb 20, 2020 6,701,917 ⤷  Try for Free
Glaxo Grp Ltd FLOVENT HFA fluticasone propionate AEROSOL, METERED;INHALATION 021433-003 May 14, 2004 7,350,676*PED ⤷  Try for Free
Teva Pharm ARMONAIR DIGIHALER fluticasone propionate POWDER;INHALATION 208798-005 Feb 20, 2020 8,006,690 ⤷  Try for Free
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 6,715,485 ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for fluticasone propionate

Country Patent Number Title Estimated Expiration
Poland 2817053 ⤷  Try for Free
Cyprus 1108995 ⤷  Try for Free
Israel 247395 משאף המכיל מונה מינון ושיטה להרכבתו (Inhaler with dose counter and method for its assembly) ⤷  Try for Free
San Marino T201500025 Contatori di dosi per inalatori e inalatori ⤷  Try for Free
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for fluticasone propionate

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1305329 08C0014 France ⤷  Try for Free PRODUCT NAME: FLUTICASONE FUROATE; REGISTRATION NO/DATE: EU/1/07/434/001 20080111
2506844 2018C/022 Belgium ⤷  Try for Free PRODUCT NAME: EEN FARMACEUTISCH COMBINATIEPRODUCT DAT EEN FARMACEUTISCH AANVAARDBAAR ZOUT VAN UMECLIDINIUM (BV. UMECLIDINIUMBROMIDE), VILANTEROL OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN (BV. VILANTEROLTRIFENATAAT) EN FLUTICASONEFUROAAT OMVAT; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117
1519731 92269 Luxembourg ⤷  Try for Free PRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
2506844 132018000000341 Italy ⤷  Try for Free PRODUCT NAME: UN PRODOTTO DI COMBINAZIONE FARMACEUTICA COMPRENDENTE UN SALE FARMACEUTICAMENTE ACCETTABILE DI UMECLIDINIO (AD ESEMPIO BROMURO DI UMECLIDINIO), VILANTEROLO O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE (AD ESEMPIO VILANTEROLO TRIFENATATO) E UN FUROATO(TRELEGY ELLIPTA - FLUTICASONE FUROATO/UMECLIDINIO/VILANTEROLO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1236, 20171117
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Market Dynamics and Financial Trajectory of Fluticasone Propionate

Last updated: July 3, 2025

Introduction

Fluticasone propionate, a synthetic corticosteroid, has transformed respiratory care since its introduction in the 1990s. As a key player in treating asthma, allergic rhinitis, and chronic obstructive pulmonary disease (COPD), this drug drives significant revenue for pharmaceutical giants. Investors and business leaders must understand its market dynamics and financial path to navigate evolving challenges like patent expirations and generic competition. This analysis delves into current trends, financial performance, and future prospects, offering actionable insights for informed decision-making in the pharmaceutical sector.

Overview of Fluticasone Propionate

Fluticasone propionate functions as an inhaled glucocorticoid, reducing inflammation in the airways by inhibiting inflammatory mediators. First approved by the FDA in 1994 for nasal spray formulations, it gained prominence through products like Flonase and Advair, developed by GlaxoSmithKline (GSK). Its efficacy in managing symptoms of asthma and nasal allergies has made it a cornerstone of respiratory therapy, with annual prescriptions reaching millions globally.

The drug's market success stems from its broad applications, including monotherapy and combinations with bronchodilators like salmeterol. GSK's strategic positioning has leveraged fluticasone propionate to capture a substantial share of the $50 billion global respiratory market, as reported in recent industry analyses. However, its trajectory reflects broader industry shifts, including rising demand for biologics and personalized medicine, which could influence its long-term dominance.

Current Market Dynamics

The market for fluticasone propionate remains robust, driven by increasing respiratory disease prevalence amid urbanization and pollution. In 2023, the global market for inhaled corticosteroids like fluticasone propionate exceeded $10 billion, with North America and Europe accounting for over 60% of sales. Key drivers include aging populations and lifestyle factors, such as smoking and environmental allergens, which boost demand for effective treatments.

Competition intensifies from both branded and generic players. GSK leads with products like Advair, but Teva Pharmaceuticals and Mylan have introduced affordable generics following patent expirations. For instance, the U.S. market saw a 25% drop in fluticasone propionate's branded sales volume in 2022, as generics captured 40% market share, according to IQVIA data. Regulatory factors, including FDA approvals for biosimilars and stricter environmental regulations on inhaler propellants, add complexity, potentially reshaping supply chains and pricing strategies.

Emerging markets in Asia-Pacific, particularly China and India, present growth opportunities. Here, rising healthcare access and government initiatives for chronic disease management have propelled fluticasone propionate sales by 15% annually. Yet, challenges like counterfeit drugs and varying reimbursement policies temper this expansion, forcing companies to adapt through partnerships and localized manufacturing.

Financial Trajectory

Fluticasone propionate has delivered steady financial returns for GSK, contributing significantly to its respiratory portfolio. In 2023, global sales of fluticasone-based products topped $4.5 billion, per GSK's annual report, representing a 5% year-over-year increase despite generic erosion. This resilience stems from premium pricing in developed markets and volume growth in emerging economies, where per-capita healthcare spending rises.

Historically, the drug's financial peak occurred in the early 2010s, with Advair alone generating over $8 billion annually before patent cliffs. Post-2017, when key patents expired in major markets, revenues declined by 30% due to generic influx. GSK countered this by innovating combination therapies and expanding into over-the-counter (OTC) segments, such as Flonase Allergy Relief, which saw a 10% sales uptick in 2023.

Looking at projections, analysts from Statista forecast a compound annual growth rate (CAGR) of 3-5% for fluticasone propionate through 2030, driven by unmet needs in COPD and pediatric asthma. However, financial risks loom, including inflation-driven cost pressures and potential biosimilar competition. GSK's recent earnings reports show a 12% net profit margin on respiratory drugs, bolstered by cost efficiencies and strategic acquisitions, underscoring the drug's role in maintaining overall corporate profitability.

Patent Landscape and Regulatory Factors

Patents have been pivotal in shaping fluticasone propionate's financial trajectory. GSK's original composition-of-matter patent expired in 2010 in the U.S., triggering a wave of generic entries. Subsequent formulation patents, such as those for dry-powder inhalers, extended exclusivity until 2023 in some regions, providing temporary revenue protection. The European Patent Office's database highlights ongoing litigation, with GSK defending against challenges from generic firms like Sandoz.

Regulatory hurdles further influence dynamics. The FDA's Orange Book lists multiple approvals for fluticasone propionate, including recent generic nods that mandate bioequivalence testing. In Europe, the EMA's emphasis on environmental sustainability has prompted reforms, such as phasing out hydrofluoroalkane (HFA) propellants, potentially increasing R&D costs for manufacturers. These factors could erode margins, as companies invest in greener alternatives.

Globally, harmonization efforts like those from the International Council for Harmonisation (ICH) aim to streamline approvals, benefiting fluticasone propionate's market entry in developing regions. Yet, pricing regulations in countries like Canada and Australia, which enforce reference pricing, limit profitability, compelling firms to adopt dynamic pricing models.

Future Outlook

The horizon for fluticasone propionate involves both opportunities and uncertainties. As telemedicine and digital health tools gain traction, demand for user-friendly inhalers could rise, potentially offsetting generic pressures. GSK is investing in next-generation formulations, such as once-daily doses, to recapture market share and extend product lifecycles.

However, threats from novel therapies, like biologics for severe asthma, challenge its position. Reports from Grand View Research indicate that the biologics segment will grow at a 10% CAGR, potentially cannibalizing traditional corticosteroid sales. Geopolitical factors, including supply chain disruptions from the COVID-19 aftermath, add volatility, with raw material shortages impacting production costs.

On the upside, partnerships with tech firms for smart inhalers—equipped with sensors for adherence tracking—could enhance patient outcomes and create new revenue streams. By 2030, experts predict fluticasone propionate will maintain a 20% share in the respiratory market, provided companies navigate regulatory landscapes adeptly and innovate proactively.

Key Takeaways

  • Fluticasone propionate sustains strong market presence despite generic competition, with 2023 sales exceeding $4.5 billion globally.
  • Patent expirations have driven a 25% sales decline in key markets, but strategic innovations and emerging market growth offer counterbalance.
  • Financial projections indicate a 3-5% CAGR through 2030, tempered by regulatory and environmental challenges.
  • Competition from biologics and generics underscores the need for R&D investment to preserve profitability.
  • Business leaders should monitor regulatory shifts and partnerships to capitalize on opportunities in digital health and sustainability.

FAQs

1. What factors are driving the current demand for fluticasone propionate?
Demand rises from increasing respiratory disease rates, driven by pollution and aging populations, particularly in Asia-Pacific markets.

2. How have generic entries affected fluticasone propionate's revenue?
Generics have reduced branded sales by about 30% since 2017, prompting GSK to shift focus to OTC products and combination therapies.

3. What role do patents play in fluticasone propionate's market dynamics?
Expired patents have enabled generic competition, but ongoing formulation patents provide partial protection in select regions until 2023.

4. Are there financial risks associated with fluticasone propionate's future?
Yes, risks include pricing pressures from regulations and potential market share loss to biologics, which could slow growth to below 5% CAGR.

5. How might regulatory changes impact the drug's trajectory?
Stricter environmental rules on inhaler propellants may raise costs, but they also open doors for innovative, sustainable formulations.

Sources

  1. GSK Annual Report 2023.
  2. IQVIA Market Prognosis Report, 2023.
  3. Statista Pharmaceutical Market Analysis, 2024.
  4. Grand View Research Respiratory Drugs Forecast, 2024.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.